Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient

CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Zhang, Jian-Ping, Zhang, Rui, Tsao, Shih-Ting, Liu, Yu-Chen, Chen, Xiaochuan, Lu, Dao-Pei, Castillo, Paul, Chang, Lung-Ji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Exceptional Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058233/
https://ncbi.nlm.nih.gov/pubmed/30026294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017004
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia